Sorrento Therapeutics Names COO

San Diego-based Sorrento Therapeutics said today that it has named Dr. Jeffrey Su as its new Executive Vice President and Chief Operating Officer. Su was previously Chief Scientific and Development Officer at Cytovance Biologics, and also served at Sanofi Pasteur, Femta Biopharmaceutical, Cancervax Corp., The Dow Chemical Company, Tanox, and Human Genome Science. The company said Su will lead its in-house bioprocess and manufacturing operations.